Olomorasib combined with Keytruda targets KRAS G12C-mutant NSCLC, receiving FDA Breakthrough Therapy designation for its promising efficacy in early trials. The designation is based on LOXO-RAS-20001 ...
Rebecca Myerson, University of Wisconsin–Madison, Madison, Wisconsin. Andrew Feher ([email protected]), Department of Health Care Access and Information, Sacramento, California. In the Affordable Care ...
Hosted on MSN
A Fayetteville man, and leader of Blood gang subset, sentenced to 30 years in federal prison
A Fayetteville man, believed to be the leader of a drug trafficking organization that distributed thousands of pounds of high-grade marijuana in the city, was sentenced last week to 30 years in prison ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback